Αρχική World News Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful Treatment

Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful Treatment

Researchers have found that combining chemo and light therapy into one treatment called Ru-Pt makes a more powerful impact on cancer cells than either therapy alone.Combining therapies can be beneficial because it makes it possible to reach some cancers that are drug-resistant, and can also reduce side effects. Researchers found that to be true for Ru-Pt.The chemo component is cisplatin (brand name Platinol), which contains platinum. It’s one of the most common chemo drugs. It binds to the DNA in tumor cells and damages it so badly that the cell can’t repair itself, which triggers cell death. A chemical enhancer called phenylbutyrate is often combined with cisplatin to increase its efficacy. It was also used in this study.In photodynamic therapy (PDT), a metal complex is delivered directly to the cell. It’s then activated by laser light, which triggers the formation of oxygen. This damages the cell’s metabolism and triggers cell death. The PDT used in this particular study was a ruthenium metal complex.The drugs were combined so that they would reach the cells simultaneously and therefor increase their impact — something other clinical trials don’t typically do.“In clinical protocols, each drug is administered separately and may not reach the tumor at the same time or at a fixed ratio,” said lead author Gilles Gasser, a professor from the Paris Sciences et Lettres (PSL) University in Paris, France.sc name=”content-ad-horiz-1″]Photo: Adobe Stock/ JenniferThe study was published in Angewandte Chemie, one of the best chemistry journals in the world, that’s produced by the German Chemical Society.Researchers at the Paris Sciences et Lettres (PSL) University led by Gilles Gasser and researchers from Hebrew University in Jerusalem led by Professor Dan Gibson collaborated on the study.They combined cisplatin, phenylbutyrate, and the PDT drug into one compound that they dubbed Ru-Pt. Then they tested to see how it would interact with cells in a lab setting. (The goal for treatment would be to inject it into a patient’s bloodstream where it will reach the targeted tumor cells and wreak havoc in one neat package).sc name=”content-ad-horiz-2″]Photo: Adobe Stock/choknitiCisplatin (paired with phenylbutyrate) and the PDT drug are connected by a molecular spacer so that they can reach the cells at the same time without affecting the other drug’s work. This also help reduce side effects.“The correct spacer length was critical to ensure that both drug compounds will not interfere with each other, but the molecule remains small, water-soluble, and able to travel across membranes,” Gasser said.The researchers tested the treatment in the lab, on healthy cells and cancer cells. Once the drugs reached the tumor, the chemo portion got to work immediately while they shined a laser light on the same spot to activate the PDT.Photo: Adobe Stock/Jennifersc name=”content-ad-horiz-3″]They found that Ru-Pt had a deadly impact on cancer cells. It had an especially lethal impact on cancer cell lines that were resistant to other drugs — Ru-Pt destroyed up to 10 times more cancer cells than the treatments could on their own.The results are promising and show the high potential of combining drug treatments into one effective package.More research needs to be done, as this was done on cells in a lab environment. We look forward to hearing more developments in this research.Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

5-Year-Old Boy Surprised With Paycheck For Helping Electrical Company Fix His House

A young boy in England got quite the surprise when he was handed a check for a job well done! The boy’s mom, Laura-Nicole, shared...

SABCS 2021: New Research and Updates in Breast Cancer Treatment and Side Effects

The 2021 San Antonio Breast Cancer Symposium (SABCS) was held from December 7 to 10 in San Antonio, Texas, and online. In this podcast,...

Cancer Research UK publishes gender and ethnicity pay gap reports

As part of Cancer Research UK’s ongoing commitment to improving the diversity of the organisation, the charity has today published its gender pay gap...

Can mRNA Vaccines Help Treat Cancer?

January 20, 2022, by NCI Staff A technician working on mRNA vaccine production. Credit: Image used with permission from BioNTech The coronavirus pandemic has thrown a spotlight...

A Phase III Study of Spartalizumab in Combination with Dabrafenib and Trametinib Did Not Meet Primary Endpoint in BRAF V600–Mutated Metastatic Melanoma

COMBI-i did not show a statistically significant difference in investigator-assessed progression-free survival (PFS) in the broad population of patients with BRAF V600–mutated metastatic melanoma treated in...

Wawa Employee Saves Life Of Customer Who Stopped Breathing After A Seizure

When 19-year-old John Wallop arrived for his 16-hour shift behind the deli counter at Wawa in Millville, New Jersey, he thought it would just...